GUILDFORD, UK / ACCESSWIRE / November 9, 2023 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for use in ...
SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE: A) today announced it has received CE-IVD mark approval for the PD-L1 IHC 28-8 pharmDx to guide options for the first-line ...
MONMOUTH JUNCTION, N.J., March 12, 2025 /PRNewswire/ -- Researchers from Creatv Bio, Division of Creatv MicroTech, Inc. (Monmouth Junction, NJ) and The Mayo Clinic (Jacksonville, FL), in collaboration ...
Two viewpoint articles published in JAMA Oncology provide opposing opinions on the benefit of testing for programmed death-ligand 1 (PD-L1) expression in patients with non-small-cell lung cancer ...
该研究揭示了PD-L1在肿瘤细胞免疫逃避中的一个以前未知的功能，扩大了对免疫检查点阻断疗法内在抵抗机制的理解。 抗PD-1/PD-L1免疫检查点阻断的耐药性仍然是影响其临床应用疗效的关键挑战。迄今为止表征的大多数耐药机制主要涉及PD-L1以外的外部因素。
GUILDFORD, UK / ACCESSWIRE / November 9, 2023 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for use in ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈